Login / Signup
The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease.
Timothy Daly
Stéphane Epelbaum
Published in:
AJOB neuroscience (2022)
Keyphrases
</>
cognitive decline
mild cognitive impairment